pharma · Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation · Myelodysplastic Syndrome · PMVP
PMV Pharmaceuticals drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
PMV Pharmaceuticals drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
Development asset linked to PMV Pharmaceuticals in public FDA and regional records.
Development asset linked to PMV Pharmaceuticals in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
US regulatory status: approved. Molecular target: Mitochondrial complex I (NADH dehydrogenase).
Development asset linked to PMV Pharmaceuticals in public FDA and regional records.